ARS Pharmaceuticals, Inc. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax
ARS Pharmaceuticals, Inc. (SPRY) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of $200.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2025-09-30 was -$100.00K, a 120.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2025-06-30 was $100.00K.
- ARS Pharmaceuticals, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2025-03-31 was $100.00K.
- ARS Pharmaceuticals, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2024-12-31 was -$100.00K, a 150.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2024 was $200.00K.
- ARS Pharmaceuticals, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2023 was -$400.00K, a 200.00% decline from fiscal 2022.
- ARS Pharmaceuticals, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2022 was $400.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $200.00K 10-Q · filed 2025-11-10 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $100.00K 10-Q · filed 2026-08-13 | -$100.00K 10-Q · filed 2025-08-13 | $300.00K 10-Q · filed 2026-08-13 | -$300.00K 10-Q · filed 2025-08-13 | $100.00K derived: sum of 3 quarters · filed 2026-08-13 | $600.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | $500.00K derived: sum of 3 quarters · filed 2026-05-15 | $500.00K derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $400.00K derived: sum of 2 quarters · filed 2026-03-09 | $400.00K derived: sum of 3 quarters · filed 2026-03-09 | $200.00K 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $500.00K 10-Q · filed 2025-11-10 | $500.00K derived: sum of 2 quarters · filed 2025-11-10 | $300.00K 10-Q · filed 2025-11-10 | $500.00K derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | $200.00K 10-Q · filed 2024-08-06 | -$200.00K 10-Q · filed 2025-08-13 | $200.00K 10-Q · filed 2024-08-06 | $0.00 derived: sum of 3 quarters · filed 2025-08-13 | $600.00K derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | -$200.00K 10-Q · filed 2025-05-14 | $200.00K 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-05-14 | $600.00K derived: sum of 3 quarters · filed 2025-05-14 | $800.00K derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $800.00K derived: sum of 2 quarters · filed 2025-03-20 | $1.00M derived: sum of 3 quarters · filed 2025-03-20 | -$400.00K 10-K · filed 2025-03-20 | $400.00K 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $600.00K 10-Q · filed 2023-11-09 | $800.00K derived: sum of 2 quarters · filed 2024-08-06 | -$600.00K 10-Q · filed 2024-11-13 | $600.00K 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $200.00K 10-Q · filed 2024-08-06 | $600.00K 10-Q · filed 2024-08-06 | ||||||
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | $400.00K 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |